Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome
- PMID: 37573872
- DOI: 10.1111/jop.13467
Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome
Abstract
Background: Translationally controlled tumour protein (TCTP) is a multifunctional protein elevated in multiple cancers. However, studies on its role in oral carcinogenesis and prognosis are rare. We recently reported the role of its interacting partner, MCL1, in oral cancer progression and outcome. Hence, the present study aimed to assess TCTP expression in oral tumorigenesis and its association with patient outcomes alone and in combination with MCL1.
Methods: TCTP expression was assessed by immunohistochemistry and immunoblotting in oral tissues and cells, respectively. Cell viability post siRNA/dihydroartemisinin treatment was analysed by tetrazolium salt assay. Cell survival, invasion and tumorigenic potential post TCTP knockdown were assessed by clonogenic, Matrigel and soft-agar assays, respectively. The association of TCTP with patient outcome was analysed by Kaplan-Meier and Cox regression.
Results: TCTP was significantly overexpressed in oral premalignant lesions (p < 0.0001), oral tumours (p < 0.0001) and oral dysplastic and cancer cells versus normal oral mucosa and also in recurrent (p < 0.05) versus non-recurrent oral tumours. Further, elevated TCTP was significantly (p < 0.05) associated with poor recurrence free survival (RFS) and poor overall survival (OS; hazard ratio = 2.29; p < 0.05). Intriguingly, the high co-expression of TCTP and MCL1 further reduced the RFS (p < 0.05) and OS (p < 0.05; hazard-ratio = 3.49; p < 0.05). Additionally, TCTP knockdown decreased survival (p < 0.05), invasion (p < 0.01) and in vitro tumorigenic potential (p < 0.0001). Dihydroartemisinin treatment reduced TCTP levels and viability of oral cancer cells.
Conclusion: Our studies demonstrate an oncogenic role of TCTP in oral cancer progression and poor outcome. Thus, TCTP may be a potential prognostic marker and therapeutic target in oral cancers.
Keywords: TCTP; invasion; oral squamous cell carcinoma; prognosis; recurrence.
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.J Exp Clin Cancer Res. 2017 May 15;36(1):68. doi: 10.1186/s13046-017-0531-3. J Exp Clin Cancer Res. 2017. PMID: 28506239 Free PMC article.
-
Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.Cell Commun Signal. 2017 Feb 1;15(1):9. doi: 10.1186/s12964-017-0164-3. Cell Commun Signal. 2017. PMID: 28143584 Free PMC article.
-
Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration via regulation of the DLC1/TCTP/Cdc42 pathway.Food Funct. 2020 Nov 18;11(11):9573-9584. doi: 10.1039/d0fo00996b. Food Funct. 2020. PMID: 33150340
-
Translationally controlled tumor protein: the mediator promoting cancer invasion and migration and its potential clinical prospects.J Zhejiang Univ Sci B. 2022 Aug 15;23(8):642-654. doi: 10.1631/jzus.B2100910. J Zhejiang Univ Sci B. 2022. PMID: 35953758 Free PMC article. Review.
-
The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation.Results Probl Cell Differ. 2017;64:69-126. doi: 10.1007/978-3-319-67591-6_4. Results Probl Cell Differ. 2017. PMID: 29149404 Review.
Cited by
-
Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy.Cancer Cell Int. 2024 Jun 4;24(1):198. doi: 10.1186/s12935-024-03355-9. Cancer Cell Int. 2024. PMID: 38835077 Free PMC article. Review.
References
REFERENCES
-
- Mohan P, Lando HA. Oral Tobaccco and mortality in India. Indian J Clin Med. 2016;7:IJCM.S25889. doi:10.4137/IJCM.S25889
-
- Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14:47-62. doi:10.1177/154411130301400105
-
- de Oliveira LQR, Almangush A, Al-Samadi A, Salo T, Coletta RD. Prognostic markers for oral cancer: An overview of the current status and directions for future research. J Oral Pathol Med. 2023;52:288-293. doi:10.1111/jop.13406
-
- Tanaka T, Ishigamori R. Understanding carcinogenesis for fighting oral cancer. J Oncol. 2011;2011:603740. doi:10.1155/2011/603740
-
- Shetty KSR, Kurle V, Greeshma P, et al. Salvage surgery in recurrent oral squamous cell carcinoma. Front Oral Health. 2022;2:815606. doi:10.3389/froh.2021.815606
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
